VANDA PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
VANDA PHARMACEUTICALS INC. (VNDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 50.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2023-03-31 was 47.00%, a 0.00% change year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2022-03-31 was 47.00%, a 2.17% increase year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2021-03-31 was 46.00%, a 11.54% decline year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2020-03-31 was 52.00%, a 10.34% decline year-over-year.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2024 was 50.00%, a 6.38% increase from fiscal 2023.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2023 was 47.00%, a 2.17% increase from fiscal 2022.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2022 was 46.00%, a 0.00% change from fiscal 2021.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2021 was 46.00%, a 9.80% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 50.00% 10-K · filed 2026-02-12 | |||
| 2024-09-30 | 50.00% 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | 50.00% 10-Q · filed 2025-07-31 | |||
| 2023-12-31 | 47.00% 10-K · filed 2026-02-12 | |||
| 2023-09-30 | 47.00% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 47.00% 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | 47.00% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 46.00% 10-K · filed 2025-02-14 | |||
| 2022-09-30 | 46.00% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 46.00% 10-Q · filed 2023-07-28 | |||
| 2022-03-31 | 47.00% 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | 46.00% 10-K · filed 2024-02-08 | |||
| 2021-09-30 | 46.00% 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 46.00% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 46.00% 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | 51.00% 10-K · filed 2023-02-09 | |||
| 2020-09-30 | 51.00% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 52.00% 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | 52.00% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 58.00% 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 58.00% 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | 59.00% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 58.00% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 58.00% 10-K · filed 2021-02-11 | |||
| 2018-09-30 | 58.00% 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 57.00% 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | 57.00% 10-Q · filed 2019-05-03 | |||
| 2017-12-31 | 57.00% 10-K · filed 2020-02-26 | |||
| 2017-09-30 | 57.00% 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | 57.00% 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | 57.00% 10-Q · filed 2018-05-02 | |||
| 2016-12-31 | 57.00% 10-K · filed 2019-02-19 | |||
| 2016-09-30 | 57.00% 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | 57.00% 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | 57.00% 10-Q · filed 2017-05-03 | |||
| 2015-12-31 | 60.00% 10-K · filed 2018-02-15 | |||
| 2015-09-30 | 60.00% 10-Q · filed 2016-11-03 | |||
| 2015-06-30 | 61.00% 10-Q · filed 2016-07-28 | |||
| 2015-03-31 | 61.00% 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | 62.00% 10-K · filed 2017-02-17 | |||
| 2014-09-30 | 64.00% 10-Q · filed 2015-11-04 | |||
| 2014-06-30 | 64.00% 10-Q · filed 2015-07-31 | |||
| 2014-03-31 | 66.00% 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | 65.00% 10-K · filed 2016-02-12 | |||
| 2013-09-30 | 63.00% 10-Q · filed 2014-10-27 | |||
| 2013-06-30 | 62.00% 10-Q · filed 2014-08-08 | |||
| 2013-03-31 | 62.00% 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | 68.00% 10-K · filed 2015-03-13 | |||
| 2012-09-30 | 68.00% 10-Q · filed 2013-11-08 | |||
| 2012-06-30 | 68.00% 10-Q · filed 2013-07-31 | |||
| 2012-03-31 | 73.00% 10-Q · filed 2013-05-10 | |||
| 2011-12-31 | 71.00% 10-K · filed 2014-02-25 | |||
| 2011-09-30 | 73.00% 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | 73.00% 10-Q · filed 2012-08-03 | |||
| 2010-12-31 | 68.00% 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |